July 17, 2017 10:00 AM EDT
R&D

CymaBay shares get a bounce on pos­i­tive PBC PhII da­ta

John Carroll

Editor & Founder

CymaBay Ther­a­peu­tics got a bad­ly need­ed boost this morn­ing af­ter its lead drug scored some pos­i­tive da­ta in a Phase II tri­al.

The Newark, CA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

As­cle­tis’ not-so-great weight loss da­ta; Vi­vace’s $35M Se­ries D

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times